The VALID BP project was initiated to increase the availability of validated blood pressure measuring devices (BPMDs). The goal is to eliminate non validated BPMDs and minimise over- and underdiagnosis of hypertension caused by inaccurate readings. This study was undertaken to assess the potential return on investment in the VALID BP project. The Framework to Assess the Impact of Translational Health Research was applied to the VALID BP project. This paper focuses on the implementation of the cost benefit analysis aspect of this framework to monetise past research investment and model future research costs, implementation costs, and benefits. Analysis was based on reasoned assumptions about potential impacts from availability and use of validated BPMDs (assuming an end goal of 100% validated BPMDs available in Australia by 2028) and improved skills leading to more accurate BP measurement. After 5 years, with 20% attribution of benefits, there is a potential $1.14–$1.30 return for every dollar spent if the proportion of validated BPMDs and staff trained in proper BP measurement technique increased from 20% to 60%. After eight years (2020–2028) and assuming universal validation and training coverage, the returns would be between $2.70 and $3.20 per dollar spent (not including cost of side effects of unnecessary medication or downstream patient impacts from unmanaged hypertension). This modelled economic analysis indicates there will be positive downstream economic benefits if the availability of validated BPMDs is increased. The findings support ongoing efforts toward a universal regulatory framework for BPMDs and can be considered within more detailed future economic analyses.

VALID BP 项目的启动是为了提高经过验证的血压测量设备 (BPMD) 的可用性。目标是消除未经验证的 BPMD，并最大限度地减少因读数不准确而导致的高血压过度诊断和漏诊。本研究旨在评估 VALID BP 项目的潜在投资回报。评估转化健康研究影响的框架已应用于 VALID BP 项目。本文重点介绍该框架的成本效益分析方面的实施，以将过去的研究投资货币化，并对未来的研究成本、实施成本和效益进行建模。分析基于对经过验证的 BPMD 的可用性和使用的潜在影响的合理假设（假设最终目标是到 2028 年澳大利亚 100% 提供经过验证的 BPMD）以及改进的技能，从而实现更准确的血压测量。5 年后，按照 20% 的福利分配，如果经过验证的 BPMD 和接受适当血压测量技术培训的员工比例从 20% 增加到 60%，则每花费 1 美元，潜在回报为 1.14-1.30 美元。八年后（2020-2028 年）并假设普遍验证和培训覆盖，每花费 1 美元，回报将在 2.70 美元至 3.20 美元之间（不包括不必要的药物副作用的成本或未控制的高血压对下游患者的影响）。该模型经济分析表明，如果增加经过验证的 BPMD 的可用性，将会产生积极的下游经济效益。研究结果支持了为 BPMD 建立通用监管框架所做的持续努力，并且可以在未来更详细的经济分析中予以考虑。